{
    "clinical_study": {
        "@rank": "31752", 
        "arm_group": [
            {
                "arm_group_label": "Part 1 (Once-daily dosing regimen, high concentration)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Part 2 (Twice-daily dosing regimen, high concentration)", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Part 3 (Once-daily dosing regimen, low concentration)", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of this trial is to investigate the\n      pharmacodynamic (the effect of the investigated drug on the body) of insulin degludec\n      (insulin 454), an explorative formulation, not similar to the proposed commercial\n      formulation, under single-dose and steady-state conditions in male subjects with type 1\n      diabetes."
        }, 
        "brief_title": "Investigation of Pharmacodynamic Characteristics of Explorative Formulation of Insulin Degludec in Male Subjects With Type 1 Diabetes", 
        "completion_date": {
            "#text": "January 2007", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 1"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and are considered to be generally healthy, except for the underlying diabetes\n             mellitus, based on an assessment of medical history, physical examination and\n             clinical laboratory data, as judged by the Investigator\n\n          -  Diagnosed with type 1 diabetes mellitus and treated with insulin for at least 12\n             months\n\n          -  Body Mass Index (BMI) between 18.0 and 27.0 kg/m^2 (both inclusive)\n\n          -  Glycosylated haemoglobin A1c (HbA1c) below or equal to 10.0 % based on central\n             laboratory results\n\n        Exclusion Criteria:\n\n          -  History of significant multiple drug allergies or with a known or suspected allergy\n             to the trial product or any medicine chemically related to the trial product, as\n             judged by the Investigator\n\n          -  Participation in any other trials involving investigational products within 3 months\n             preceding the start of dosing"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "69 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01865318", 
            "org_study_id": "NN5401-1740", 
            "secondary_id": "2006-002212-97"
        }, 
        "intervention": {
            "arm_group_label": [
                "Part 1 (Once-daily dosing regimen, high concentration)", 
                "Part 2 (Twice-daily dosing regimen, high concentration)", 
                "Part 3 (Once-daily dosing regimen, low concentration)"
            ], 
            "description": "Administered subcutaneously (s.c., under the skin)", 
            "intervention_name": "insulin degludec", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Insulin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 27, 2013", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany", 
                    "zip": "41460"
                }
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Single Centre, Open-Label, Multiple Dose Trial Examining the Pharmacodynamic Characteristics of Insulin 454 Under Single-Dose and Steady-State Conditions in Male Subjects With Type 1 Diabetes", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Hanne Haahr", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2007", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Area under the glucose infusion rate curve", 
            "safety_issue": "No", 
            "time_frame": "0-24 hours after dosing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01865318"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum glucose infusion rate (GIRmax)", 
                "safety_issue": "No", 
                "time_frame": "0-24 hours after dosing"
            }, 
            {
                "measure": "Time to maximum glucose infusion rate (tGIRmax)", 
                "safety_issue": "No", 
                "time_frame": "0-24 hours after dosing"
            }, 
            {
                "measure": "Area under the serum insulin degludec curve", 
                "safety_issue": "No", 
                "time_frame": "0-96 hours after dosing"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2006", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}